2-(chloromethyl)-6-fluorobenzoxazole | 143708-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-(chloromethyl)-6-fluorobenzoxazole
• 英文别名: 2-(chloromethyl)-6-fluorobenzo[d]oxazole；2-(Chloromethyl)-6-fluoro-1,3-benzoxazole
• CAS: 143708-36-5
• 化学式: C₈H₅ClFNO
• mdl: MFCD18861556
• 分子量: 185.585
• InChiKey: JVUWLFQJNVEUSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(chloromethyl)-6-fluorobenzoxazole 在 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 5.5h， 生成 6-fluoro-2-((1E,3E)-4-(pyridine-2-yl)-1,3-butadienyl)benzo[d]oxazole
  参考文献：
  名称：

  Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation

  摘要：

  Aggregation of alpha-synuclein (alpha-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good pi-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards alpha-Syn with IC50 down to 1.09 mu M. The molecule is found binding in parallel to the NACore within NAC domain of alpha-Syn, interfering aggregation of NAC region within different alpha-Syn monomer, and further inhibiting or slowing down the formation of alpha-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit alpha-Syn aggregation.

  DOI：

  10.1016/j.bmc.2019.05.032
• 作为产物：
  描述：

  2-氨基-5-氟苯酚 、 2-氯-1-乙氧基乙胺 反应 6.0h， 以80%的产率得到2-(chloromethyl)-6-fluorobenzoxazole
  参考文献：
  名称：

  Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation

  摘要：

  Aggregation of alpha-synuclein (alpha-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good pi-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards alpha-Syn with IC50 down to 1.09 mu M. The molecule is found binding in parallel to the NACore within NAC domain of alpha-Syn, interfering aggregation of NAC region within different alpha-Syn monomer, and further inhibiting or slowing down the formation of alpha-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit alpha-Syn aggregation.

  DOI：

  10.1016/j.bmc.2019.05.032

文献信息

• Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogs of 3-aminopyridin-2(1H)-one
  作者：Walfred S. Saari、John S. Wai、Thorsten E. Fisher、Craig M. Thomas、Jacob M. Hoffman、Clarence S. Rooney、Anthony M. Smith、James H. Jones、Dona L. Bamberger

  DOI：10.1021/jm00099a007

  日期：1992.10

  A series of nonnucleoside 3-aminopyridin-2(1H)-one derivatives was synthesized and evaluated for HIV-1 RT inhibitory properties. Several analogs proved to be potent and highly selective antagonists with in vitro IC50 values as low as 19 nM in the enzyme assay using rC.dG as template-primer. Two compounds from this series, 3-[[(4,7-dimethylbenzoxazol-2-yl)methyl]-amino]-5-ethyl-6-methy lpyridin-2(1H)-one

  合成了一系列非核苷3-氨基吡啶-2（1H）-一衍生物，并评估了其对HIV-1 RT的抑制作用。在使用rC.dG作为模板引物的酶分析中，几种类似物被证明是有效的高选择性拮抗剂，体外IC50值低至19 nM。该系列中的两种化合物，3-[[[（4,7-二甲基苯并恶唑-2-基）甲基]-氨基] -5-乙基-6-甲基吡啶2-2（1H）-一个（34，L-697,639）和相应的4,7-二氯类似物（37，L-697,661）在浓度为25-50 nM的MT4细胞培养物中可抑制HIV-1 IIIb感染的传播达95％，并被选作临床试验的抗病毒药。
• [EN] ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'ALDOSE RÉDUCTASE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV COLUMBIA

  公开号：WO2017223179A1

  公开（公告）日：2017-12-28

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

  本公开涉及新颖化合物及其制药组合物，以及促进皮肤健康老化、治疗皮肤疾病、心血管疾病、肾脏疾病、血管生成障碍（如癌症）、组织损伤（如非心脏组织损伤）、急性心肌梗死、缺血性损伤以及其他各种疾病（例如由糖尿病引起的并发症）的治疗方法，所述的化合物和组合物。其他疾病可以包括但不限于动脉粥样硬化、冠状动脉疾病、糖尿病肾病、糖尿病神经病、糖尿病视网膜病变、糖尿病心肌病、皮肤感染、周围血管疾病、中风、哮喘等。
• Aldose reductase inhibitors and methods of use thereof
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10150779B2

  公开（公告）日：2018-12-11

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

  本公开涉及新型化合物及其药物组合物，以及促进皮肤健康老化、治疗皮肤疾病、治疗心血管疾病、治疗肾脏疾病、治疗血管生成疾病（如癌症）、治疗组织损伤（如非心脏组织损伤）、治疗演变性心肌梗塞、治疗缺血性损伤，以及用本发明化合物和组合物治疗各种其他疾病（如糖尿病引起的并发症）的方法。其他疾病包括但不限于动脉粥样硬化、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、糖尿病心肌病、皮肤感染、外周血管疾病、中风、哮喘等。
• [EN] COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE TRADUCTION DE COLLAGÈNE 1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ANIMA BIOTECH INC

  公开号：WO2021216665A9

  公开（公告）日：2021-12-02
• ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP3352754A1

  公开（公告）日：2018-08-01